Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia

• Status: Completed
• Trial end date: 2019-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of our study is to examine the effects of a second antibiotic, daptomycin, in combination with a beta lactam antibiotic on treating bloodstream infection caused by methicillin-susceptible S. aureus.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: McGill University Health Center; McGill University Health Centre/Research Institute of the McGill University Health Centre
• Treatments: Daptomycin

Criteria

Inclusion Criteria:

• Patient has a methicillin susceptible Staphylococcus aureus bacteremia.

Exclusion Criteria:

• Underlying terminal illness

• Significant contraindication to beta-lactam therapy (i.e. severe allergy, severe adverse drug reaction)

• Expected death before 5 days

• Microbiologically confirmed need for concomitant VANCOMYCIN or DAPTOMYCIN